ESMO 2023

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

08:00 AM

Duration 8hrs Madrid, Spain

IMreal Cohort 4: third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions

Sanjay Popat, Nicolas Girard, Stefaniya Shoshkova, Gwendoline Kok, José Luis Pérez Gracia

Oncology | Lung Cancer

Duration 8hrs Madrid, Spain

Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): results from the Phase Ib/II MORPHEUS-Lung study

Ghiringhelli, Felip E, Zer, Greillier, Greystoke A, Lim, Al-Sakaff N, Helms HJ, Pintoffl J, Gan X, Prizant H, Cho

Oncology | Lung Cancer

Duration 8hrs Madrid, Spain

Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC

Martín M, Hilz S, Collier A, Chibly A, Sohn J, Bardia A, Lim E, Chavez-MacGregor M, Martinalbo J, Pérez-Moreno PD, Moore HM

Oncology | Breast Cancer

Duration 1hr Madrid, Spain

WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS).

Jean-Yves Blay, Allan Hackshaw, Christophe Le Tourneau, Jan Geissler, Ana Ferro, Erika Schirghuber, Olga Skatkova, Rodrigo Dienstmann

Oncology | Solid Tumors

Duration 8hrs Madrid, Spain

Quality of life (QoL) and toxicity in patients (pts) with hormone receptor-positive, HER2-negative early breast cancer (HR+, HER2– eBC) treated with adjuvant (adj) endocrine therapy (ET) in the CANcer TOxicities (CANTO) study

Bertaut A, Crnjevic TB, Martin A-L, Gaudin C, Chen L

Oncology | Breast Cancer

Duration 8hrs Madrid, Spain

Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Gadgeel S, Mok T, Peters S, Nadal E, Han J-H, Alatorre-Alexander J, Leighl N, Sriuranpong V, Perol M, de Castro Junior G, de Marinis F, Tan DSW, Shagan SM, Assaf ZJ, Maclennan M, Ochi Lohmann T, Slade M, Mathisen MS, Prasad V, Dziadziuszko R

Oncology | Lung Cancer

Duration 8hrs Madrid, Spain

Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)

Gadgeel S, Zhang Q, Lin H, Fajardo O, Trinh H, Arndorfer S, Kong S, Rahman A, Li S, Archer V, Gainor J

Oncology | Lung Cancer

Duration 8mins Madrid, Spain

Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A Phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

Jung KH, Luen S, Oliveira M, Sohn JH, Im SA, Wander S, Hurvitz S, Sonnenblick A, Breton V, Collier A, Deb S, Ngo H, Schwab R, Shemesh C, Zhu J, Hernando C

Oncology | Breast Cancer

09:35 AM

Duration 10mins Hall 3 (Salamanca Auditorium)

Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

Linda Mileshkin,Tilmann Bochtler, Chantal Pauli, Gonzalo Durán-Pacheco, Cagatay Arslan, Frédéric Bigot, Nasséra Chalabi, Natalie Cook, Antoine Italiano, Ferran Losa, Juliana Janoski de Menezes,Chantal Michaud, Mustafa Özgüroğlu, Roberto A. Pazo-Cid, Jeffrey S. Ross, Kai-Keen Shiu, Michael Stahl, Marlene Thomas, Holger Moch, Alwin Krämer

Oncology | Carcinoma of Unknown Primary

02:25 PM

Duration 10mins Hall 9 (Santander Auditorium)

Atezolizumab and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031

N. Harbeck, E. Duan, K. DuPree, C-W. Chang, C.H. Barrios, H. Zhang, S. Saji, K.H. Jung, M.L. Telli, M. Liste-Hermoso, S.Y. Chui, M. Dieterich, E. Mittendorf, L. Molinero

Oncology | Breast Cancer

03:54 PM

Duration 12mins Hall 6 (Madrid Auditorium)

ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)

Prof Benjamin J. Solomon, Prof Jin Seok Ahn, Prof Rafal Dziadziuszko, Prof Fabrice Barlesi Dr Makoto Nishio, Prof Dae Ho Lee, Prof Jong-Seok Lee, Prof Wenzhao Zhong, Dr Hidehito Horinouchi, Prof Weimin Mao, Dr Maximilian Hochmair, Dr Filippo de Marinis, Dr Maria Rita Migliorino, Prof Igor Bondarenko, Dr Tania Ochi Lohmann, Ms Tingting Xu, Mr Andres Cardona, Dr Walter Bordogna, Dr Thorsten Ruf, Prof Yi-Long Wu

Oncology | Lung Cancer

09:35 AM

Duration 5mins Sevilla Auditorium - Hall 9

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)

Bernadett Szabados, Esther Nogueron Martinez, Francisco José Álvarez Márquez, Daniel Castellano Gauna, Alejo Rodríguez-Vida Rodríguez, Carmen Garcías de España, Syed A Hussain, Carlos Álvarez Fernández, Mark Linch, Teresa Bonfill, Marine Gross-Goupil, John Kelly, Rob Jones, Simon Crabb, Luis Beltran, Rachel Garonce-Hediger, Nikolas Jan Rakebrandt, Ramona Georgescu, Charlotte Ackerman, Thomas Powles

Oncology | Urogenital Cancer

08:00 AM

Duration 8hrs Madrid, Spain

A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)

Gupta S, Alhalabi O, Bamias A, Bellmunt J, Castellano D, Bedke J, Friedlander T, Garmezy B, Grivas P, Huddart R, Necchi A, Powles T, Puente J, Rosa D, Wang F, Lambertini C, Andreev-Drakhlin A, Fassò M, Loriot Y.

Oncology | Urogenital Cancer

Duration 8hrs Madrid, Spain

ESMO 2023 IMscin001 Part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised Phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Burotto M, Zvirbule Z, Busayamas C, Alvarez R, Herraez-Baranda L, Shearer-Kang E, Liu XY, Tosti N, Castro Y, Zanghi J, Felip E (Order TBC)

Oncology | Lung Cancer

Duration 8hrs Madrid, Spain

Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours

Kuboki Y, Kitano S, Ikeda M, Koyama T, Mizugaki H, Narikiyo T, Yamaguchi Y, Ishida T, Takubo R, Ogami C, Sekiya M, Nakagawa Y, Yamamoto N

Oncology | Solid Tumors

Duration 8hrs Madrid, Spain

Updated efficacy and safety data of entrectinib▼ in patients with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours

Lu S, de Braud F, Fan Y, Hu X, Ohe Y, Yu Y, Ahn M-J, Cassier P, Lin JJ, Paz-Ares L, Xue C, Bordogna W, Patel S, Zeuner H, Dong X

Oncology | Lung Cancer

08:10 AM

Duration 5mins Hall 3 (Salamanca Auditorium)

First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)

Ray-Coquard I, Pignata S, Lee J-L, Coleman R, Rothfuss E, Brown J, Kim J-W, Selle F, Lorusso D, Bermejo Perez MJ, Pautier P, Gourley C, Ayhan A, Richardson G, Yauch L, Dieterich M, Krishnan V, Calas-Zeroug O, Harter P, Gershenson D

Oncology | Ovarian Cancer

01:50 PM

Duration 5mins Hall 9 (Sevilla Auditorium)

IMpower010: exploratory analysis of disease-free survival (DFS) by TGF cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)

Nasser Altorki, Martin Reck, Heather Wakelee, Enriqueta Felip, Eric Vallieres, Rüdiger Liersch, Satoshi Oizumi, Hiroshi Tanaka, Silvia Novello, Steven McCune, Haocheng Li, Luciana Molinero, Sören Müller, Elizabeth Bennett, Barbara J. Gitlitz, Virginia McNally, Marcus Ballinger, Barzin Nabet, Minu K. Srivastava, Caicun Zhou

Oncology | Lung Cancer

I am a healthcare professional

Notice

Cookies

External site

ESMO 2023